SAN ANTONIO, Sept. 23 /PRNewswire/ -- ENTrigue Surgical, Inc. ("ENTrigue"), a San Antonio, Texas-based company that designs, develops, manufactures and distributes medical devices used for Ear, Nose and Throat surgical procedures, announced today the first clinical experience with its Ventera™ sinus dilation systems. The Company also announced that it will launch its Synaero™ Hemostatic Gel at the American Academy of Otolaryngology Annual Symposium and Exhibition ("AAO Meeting") in Boston, Massachusetts, September 26-29, 2010 attended by ENT surgeons from around the world.
The Ventera™ sinus dilation systems include a single-use balloon delivered by one of several reusable instruments utilizing ENTrigue's proprietary SerpENT® articulating technology and does not require the use of a guide wire or cannula for delivering the balloon into various sinuses. The initial clinical cases were performed by Dr. Amin Javer, a world renowned rhinologist and Director of the St. Paul's Sinus Center in Vancouver, Canada. ENTrigue is in an early-launch phase with the Ventera™ systems in Canada and plans to launch the systems to various European markets over the next few months. The Ventera™ technology is not presently available for sale in the United States.
Dr. Javer remarked, "The Ventera systems offer an elegant and intuitive approach to sinus dilation. I am excited about the potential these systems offer as minimally invasive tools for managing sinus disease."
The Company's new Synaero™ product is a hemostatic gel used to control mucosal bleeding related to sinus surgery and was co-developed with HemCon Medical Technologies Inc., a leading global developer and manufacturer of hemorrhage control products headquartered in Portland, Oregon. The Synaero™ Hemostatic Gel, as well as the Ventera™ sinus dilation balloon and related instruments, will be on display at the ENTrigue booth at the AAO Meeting.
ENTrigue also announced the addition of John T. Treace to its Board of Directors. Treace is Sr. Vice President of Global Marketing and US Sales at Wright Medical Technology, Inc. in Arlington, Tennessee, and served as Director of Marketing for Medtronic ENT for several years prior to Wright. He joins current Board members Fred Dinger, President & CEO; Donald Gonzales, M.D., Chief Medical Officer; Richard Emmitt of The Vertical Group; and Anthony Natale, M.D. of Prism VentureWorks
Friday, September 24, 2010
Focused on Latest Clinical and Diagnostic Advances in Coagulation
BEDFORD, Mass., Sept. 23 /PRNewswire/ -- Instrumentation Laboratory (IL), today announced it will host the 2nd IL Asia Pacific Hemostasis Forum on Wednesday, October 13, 2010 at the Grand Hyatt Nusa Dua, in Bali, Indonesia. The event will run from 8:00 am to 12:00 pm, local time. The forum will focus on the latest clinical and diagnostic advances and trends in hemostasis. All healthcare professionals, practicing in the Asia Pacific region are welcome to attend.
Professor Karmel Tambunan, MD, PhD, from the Division of Hematology and Medical Oncology at the University of Indonesia, Jakarta will serve as Scientific Chairman of the Forum. In addition, several prominent experts in the field will present key information and lead discussions during the Forum, including Professor Ismail Elalamy, MD, a Hematologist at the Hopital Tenon, Paris France; Associate Professor Tatsuya Atsumi, MD, PhD, from the Graduate School of Medicine at Hokkaido University, Sapporo, Japan; and, Associate Professor Chris Ward, from the Department of Haemotology and Transfusion Medicine at the Royal North Shore Hospital, Sydney, Australia.
Topics will include new approaches and developments in the diagnosis of Heparin-Induced Thrombocytopenia (HIT), as well as new and emerging markers for Antiphospholipid Syndrome (APS) and associated clinical challenges.
"We are so honored to have some of the leading clinicians from around the world sharing their expertise on HIT and APS management and diagnostics," said Santiago Ramos, Regional Manager for North East Asia. "The Forum will address many of the key issues facing clinicians today and will provide new information to help them deliver the very best patient care."
About HIT
HIT is a severe immune reaction to Heparin that can result in the paradoxical development of a thrombotic event. One of the most common of all adverse drug effects, due to the sheer volume of patients receiving Heparin therapy (over 12 million patients annually in the US alone), it has a significant impact on anticoagulant management in hospitals worldwide. If left untreated, patients with HIT may develop serious sequelae, including pulmonary embolism, myocardial infarction, or death.
Registering to Attend
Through October 1st, 2010, individuals can register to attend this Forum, by contacting Carol Lee, at wbj@werfen-china.com
Professor Karmel Tambunan, MD, PhD, from the Division of Hematology and Medical Oncology at the University of Indonesia, Jakarta will serve as Scientific Chairman of the Forum. In addition, several prominent experts in the field will present key information and lead discussions during the Forum, including Professor Ismail Elalamy, MD, a Hematologist at the Hopital Tenon, Paris France; Associate Professor Tatsuya Atsumi, MD, PhD, from the Graduate School of Medicine at Hokkaido University, Sapporo, Japan; and, Associate Professor Chris Ward, from the Department of Haemotology and Transfusion Medicine at the Royal North Shore Hospital, Sydney, Australia.
Topics will include new approaches and developments in the diagnosis of Heparin-Induced Thrombocytopenia (HIT), as well as new and emerging markers for Antiphospholipid Syndrome (APS) and associated clinical challenges.
"We are so honored to have some of the leading clinicians from around the world sharing their expertise on HIT and APS management and diagnostics," said Santiago Ramos, Regional Manager for North East Asia. "The Forum will address many of the key issues facing clinicians today and will provide new information to help them deliver the very best patient care."
About HIT
HIT is a severe immune reaction to Heparin that can result in the paradoxical development of a thrombotic event. One of the most common of all adverse drug effects, due to the sheer volume of patients receiving Heparin therapy (over 12 million patients annually in the US alone), it has a significant impact on anticoagulant management in hospitals worldwide. If left untreated, patients with HIT may develop serious sequelae, including pulmonary embolism, myocardial infarction, or death.
Registering to Attend
Through October 1st, 2010, individuals can register to attend this Forum, by contacting Carol Lee, at wbj@werfen-china.com
Subscribe to:
Posts (Atom)